Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback